Full Press Release Details
CGuard MicroNet EPS Featured in a Live Case Transmission to the 2nd DGA Interventional Congress
Aviv, Israel- June 11, 2018 - InspireMD,
Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies
and neurovascular devices, today announced that its CGuard MicroNet covered Embolic Prevention System (EPS) was
successfully featured in a live case transmission on June 8th to the 2nd DGA Interventional Congress of
the DGA-Akademie GmbH, the academy for vascular medicine in Hamburg, Germany.
focus of this angiology congress is presentation and objective discussion of new diagnostic and therapeutic strategies in arterial
and venous disease among leading endovascular physicians, interventional cardiologists, interventional radiologists and interventional
neuroradiologists from across Europe
Ralf Langhoff, Medical Director of Angiology/Vascular Medicine, St. Gertrauden-Krankenhaus in Berlin, performed a challenging
live endovascular procedure on a 77 year-old male patient with 80% restenosis of the right internal carotid artery following surgical
endarterectomy in 2017, which is considered the current gold standard. The procedure featured CGuard EPS and was transmitted
real time to the congress.
Langhoff commented, "CGuard EPS is becoming an important tool for the treatment of patients with carotid artery disease.
The patented MicroNet technology offers plaque protection, while the product exhibits no foreshortening and delivers excellent
conformability. The live case we performed went extremely well and clearly highlights the advantages of CGuard EPS in the
treatment of carotid artery disease. CGuard EPS is making carotid artery stenting an increasingly viable alternative to
the surgical carotid endarterectomy procedure."
is an honor to have our technology featured at this leading industry conference by Dr. Ralf Langhoff, one of the premier vascular
interventionalists in Europe," commented James Barry, PhD, Chief Executive Officer of InspireMD. "The DGA Interventional
Congress is one of the most prominent conferences in the field of vascular surgery and interventional medicine featuring new developments
in therapeutic strategies and technologies, and brings together top key opinion leaders from around the world."
seeks to utilize its patented MicroNet technology to make its products the industry standard for embolic protection and
to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization,
no reflow and major adverse cardiac events.
intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard ), neurovascular, and peripheral
artery procedures. InspireMD's common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants
are quoted on the NYSE American under the ticker symbol NSPR.WS.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are
subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot
be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance
of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability
to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much
larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities
and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third
party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering
our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and
foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need
to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive
or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign
currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws
and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors
that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities
and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information,
future events or otherwise.